## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 6.1% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($59.45)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Bio-Techne Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20260105T163000 | Bullish | Relevance: 100%
- Bio-Techne Corp. (TECH) saw its stock price rally by 5.67% to $63.03 on Monday, outperforming the broader market. This positive performance occurred during an overall favorable trading session, where the S&P 500 Index and Dow Jones Industrial Average also rose. This marks the second consecutive day of gains for Bio-Techne Corp.'s stock.

**2. Should Bio-Techne’s (TECH) Revenue Miss Raise Doubts About Its Scientific Platform’s Commercial Potential?**
- Source: Simply Wall Street | 20260104T225021 | Somewhat-Bearish | Relevance: 100%
- Bio-Techne recently reported softer third-quarter results with revenue 1.7% below analyst expectations, raising questions about its ability to convert its scientific platform into consistent commercial growth. Despite this, the company's expanding spatial biology collaborations offer a promising long-term growth outlook in precision medicine. Bio-Techne's narrative projects significant revenue and earnings growth by 2028, with a fair value estimate suggesting a 16% upside from its current price.

**3. Bio-Techne Corp (NASDAQ:TECH) Given Consensus Rating of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20260104T084327 | Somewhat-Bullish | Relevance: 100%
- Bio-Techne Corp (NASDAQ:TECH) has received a consensus "Moderate Buy" rating from eighteen analysts, with an average 12-month price target of $71.00. The company's stock opened at $59.65, has a market cap of $9.29 billion, and a P/E ratio of 121.7. Bio-Techne recently reported quarterly EPS of $0.42, meeting estimates, while revenue of $286.6 million missed forecasts and was down approximately 1% year-over-year.

**4. Klaviyo, Wingstop among Stephens Best Ideas for 2026**
- Source: Yahoo Finance | 20260103T120918 | Somewhat-Bullish | Relevance: 62%
- Stephens analysts have released their 2026 "Best Ideas" list, featuring one stock from each of their 23 industry teams. These selections, including Klaviyo and Wingstop, are anticipated to outperform their respective industries, the Russell 2000, and the broader markets. The comprehensive list covers companies across various sectors, from banking and healthcare to technology and consumer goods.

**5. Who Owns Dexcom? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260103T000821 | Somewhat-Bullish | Relevance: 61%
- Dexcom, a medical device company focused on continuous glucose monitoring, has seen its stock decline by 14.7% over the last year despite long-term growth expectations. The ownership structure shows significant holdings by passive institutions like Vanguard and BlackRock, with varied activity from active managers and hedge funds. Recent insider transactions are mixed, primarily sales, with some purchases at lower prices, suggesting a nuanced view on short-term valuation but continued long-term confidence.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Evercore ISI Gr | $62 | $68 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Evercore ISI Gr | down | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 29.2x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 1.47 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 29.2 |
| Current P/E | 31.9 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.6% to 6.1% (+5.6% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (6.1% > 6.0%), caution on chasing. MRS_5 at 4.9% confirms short-term momentum alignment. Outperforming sector by 5.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +F0N (Breakout).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 6.12% (CS: 91) | Strong |
| RSI_14 | 63.4 | Neutral |
| MACD Histogram | 0.35 | Bullish |
| vs SMA20 | 1.063x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.143x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $63.03
- **Stop Loss:** $59.45 (5.7% risk)
- **Target:** $66.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 240
- **Position Value:** $15,127.20
- **Portfolio %:** 15.13%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*